Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C.
暂无分享,去创建一个
E. Sagnelli | L. Perrone | L. Adinolfi | A. Marrone | S. Maione | R. Zampino | F. Rossi | G. Bellini | B. Nobili | N. Coppola | M. Pisaturo | M. Macera | G. Pasquale | A. Boemio | E. Miraglia del Giudice
[1] E. Sagnelli,et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] E. Sagnelli,et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C , 2013, Journal of viral hepatitis.
[3] E. Sagnelli,et al. Outcomes , and Response to Therapy Among Patients with Acute Exacerbation of Chronic Hepatitis C , 2013 .
[4] F. Locatelli,et al. Cannabinoid Receptor Type 2 Functional Variant Influences Liver Damage in Children with Non-Alcoholic Fatty Liver Disease , 2012, PloS one.
[5] A. Fasano,et al. The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. , 2012, Pharmacological research.
[6] S. Perrotta,et al. CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura , 2011, Haematologica.
[7] A. Mallat,et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice , 2011, Hepatology.
[8] L. Perrone,et al. Association of the cannabinoid receptor 2 (CB2) Gln63Arg polymorphism with indices of liver damage in obese children: An alternative way to highlight the CB2 hepatoprotective properties , 2011, Hepatology.
[9] A. de Gottardi,et al. Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes , 2010, Liver international : official journal of the International Association for the Study of the Liver.
[10] D. van der Poorten,et al. Hepatitis C Virus Induces the Cannabinoid Receptor 1 , 2010, PloS one.
[11] T. Tordjmann,et al. Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration , 2010, Hepatology.
[12] Hong Liu,et al. Anandamide induces cell death through lipid rafts in hepatic stellate cells , 2010, Journal of gastroenterology and hepatology.
[13] W. M. Williams,et al. Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor , 2010, Pharmacogenetics and genomics.
[14] L. Adinolfi,et al. Long‐term outcome of hepatitis B and hepatitis C virus co‐infection and single HBV infection acquired in youth , 2009, Journal of medical virology.
[15] David B. Goldstein,et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.
[16] A. Koike,et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.
[17] Thomas Berg,et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.
[18] Jacques Fellay,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.
[19] Andreas Zimmer,et al. Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis , 2009, PloS one.
[20] D. Osei-Hyiaman,et al. Endocannabinoids and the Control of Energy Homeostasis* , 2008, Journal of Biological Chemistry.
[21] G. Uhl,et al. Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors Are Involved in the Effects of Drugs of Abuse and in Depression , 2008, Annals of the New York Academy of Sciences.
[22] M. Ostrowski,et al. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. , 2008, Gastroenterology.
[23] A. Mallat,et al. Environmental factors as disease accelerators during chronic hepatitis C. , 2008, Journal of hepatology.
[24] P. Bacchetti,et al. Influence of cannabis use on severity of hepatitis C disease. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[25] R. Schwabe,et al. The endocannabinoid 2‐arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[26] P. Pacher,et al. The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.
[27] E. Blanchard,et al. Subcellular Localization of Hepatitis C Virus Structural Proteins in a Cell Culture System That Efficiently Replicates the Virus , 2006, Journal of Virology.
[28] E. Sagnelli,et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[29] S. Bird,et al. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[30] A. Gerber,et al. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders , 2005, Journal of leukocyte biology.
[31] F. Roudot-thoraval,et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C , 2005, Hepatology.
[32] R. Schwabe,et al. Anandamide induces necrosis in primary hepatic stellate cells , 2005, Hepatology.
[33] K. Reddy,et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population , 2004, Hepatology.
[34] M. Lai,et al. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. , 2004, Virology.
[35] J. Satsangi,et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP‐2, with outcome of HCV infection , 2003, Hepatology.
[36] A. Bosserhoff,et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. , 2003, Gastroenterology.
[37] R. Gish,et al. Rate of natural disease progression in patients with chronic hepatitis C. , 2003, Journal of hepatology.
[38] C. Katlama,et al. Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: Impact of protease inhibitor therapy , 2001, Hepatology.
[39] M. Gambardella,et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.
[40] J. Wong,et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.
[41] R. Smart,et al. Drug use and drinking among students in 36 countries. , 2000, Addictive behaviors.
[42] G. Ostapowicz,et al. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection , 1998, Hepatology.
[43] E. Tanaka,et al. The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses , 1996, Hepatology.
[44] K. Ishak,et al. Histological grading and staging of chronic hepatitis. , 1995 .